ライフサイエンスコーパス: peripheral nerve sheath tumor

1 eated (0 to 3 for angiosarcoma and malignant peripheral-nerve sheath tumor).

2 order, intestinal hyperplasia, and malignant peripheral nerve sheath tumor.

3 bromas/schwannomas of patients with multiple peripheral nerve sheath tumors.

4 of alpha-T-catenin/CTNNA3 in the biology of peripheral nerve sheath tumors.

5 -fixed, paraffin-embedded specimens of human peripheral nerve sheath tumors.

6 ng tibial dysplasia, scoliosis and malignant peripheral nerve sheath tumors.

7 differentiation between benign and malignant peripheral nerve sheath tumors.

8 tp53(M214K) mutant fish developed malignant peripheral nerve sheath tumors.

9 lop peripheral ganglion-associated malignant peripheral nerve sheath tumors.

10 PN can undergo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue

11 In malignant peripheral nerve sheath tumors and CNS tumors, the cance

12 optic pathway gliomas, as well as malignant peripheral nerve sheath tumors and glioblastomas.

13 plexiform neurofibromas as well as malignant peripheral nerve sheath tumors and other malignant tumor

14 , malignant fibrous histiocytomas, malignant peripheral-nerve sheath tumors, and Ewing's sarcoma.

15 c sarcomas, myxofibrosarcomas, and malignant peripheral nerve sheath tumors are characterized by comp

16 ltiple isolated neurofibromas, and malignant peripheral nerve sheath tumors are covered in this revie

17 schwannomas are benign Schwann cell-derived peripheral nerve sheath tumors arising sporadically and

18 ignant gliomas, neurofibromas, and malignant peripheral nerve sheath tumors, as well as behavioral, c

19 A novel classification scheme for peripheral nerve sheath tumors in murine models was ther

20 Plexiform neurofibromas are peripheral nerve sheath tumors initiated by biallelic mu

21 ochemistry revealed that each of 3 malignant peripheral nerve sheath tumor (MPNST) cell lines from NF

22 through RAS/MAPK/AP-1 signaling in malignant peripheral nerve sheath tumor (MPNST) cell lines.

23 library screen using NF1-deficient malignant peripheral nerve sheath tumor (MPNST) cells.

24 Malignant peripheral nerve sheath tumor (MPNST) is an aggressive s

25 Improved staging systems for malignant peripheral nerve sheath tumor (MPNST) prognostication an

26 viruses against neuroblastoma and malignant peripheral nerve sheath tumor (MPNST) xenografts.

27 10% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST).

28 ed in neurofibromatosis type 1 and malignant peripheral nerve sheath tumor (MPNST).

29 of a variety of tumors, including malignant peripheral nerve sheath tumors (MPNST) and benign neurof

30 Malignant peripheral nerve sheath tumors (MPNST) are highly invasi

31 Malignant peripheral nerve sheath tumors (MPNST) develop in approx

32 erizes Schwann cells in benign and malignant peripheral nerve sheath tumors (MPNST) from neurofibroma

33 and OHT exert cytotoxic effects in malignant peripheral nerve sheath tumors (MPNST) where estrogen is

34 d role has not been established in malignant peripheral nerve sheath tumors (MPNST) where NF1 mutatio

35 e clinical evaluation of HDACis in malignant peripheral nerve sheath tumors (MPNST), a class of highl

36 ng growths that can transform into malignant peripheral nerve sheath tumors (MPNST), a main cause of

37 phologic and molecular features of malignant peripheral nerve sheath tumors (MPNST).

38 s develop benign neurofibromas and malignant peripheral nerve sheath tumors (MPNST).

39 tem resulting in neurofibromas and malignant peripheral nerve sheath tumors (MPNST).

40 tial for malignant transformation (malignant peripheral nerve sheath tumor; MPNST), its neoplastic na

41 We tested this in mouse malignant peripheral nerve sheath tumors (MPNSTs) and found that 1

42 status of cell cycle regulators in malignant peripheral nerve sheath tumors (MPNSTs) and neurofibroma

43 4A gene alterations in a series of malignant peripheral nerve sheath tumors (MPNSTs) and neurofibroma

44 Malignant peripheral nerve sheath tumors (MPNSTs) are a type of ra

45 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive n

46 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive s

47 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive t

48 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive,

49 Malignant peripheral nerve sheath tumors (MPNSTs) are devastating

50 Malignant peripheral nerve sheath tumors (MPNSTs) are genetically

51 Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas of

52 Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue

53 significantly worse in primary RAS malignant peripheral nerve sheath tumors (MPNSTs) compared with un

54 Malignant peripheral nerve sheath tumors (MPNSTs) develop sporadic

55 In cell lines from human malignant peripheral nerve sheath tumors (MPNSTs) driven by NF1 lo

56 ologic imaging, in differentiating malignant peripheral nerve sheath tumors (MPNSTs) from benign neur

57 erived Schwann cells isolated from malignant peripheral nerve sheath tumors (MPNSTs) overexpress PDGF

58 Malignant peripheral nerve sheath tumors (MPNSTs) represent a grou

59 Here we report that malignant peripheral nerve sheath tumors (MPNSTs) that arise in ze

60 comparative methylome analysis of malignant peripheral nerve sheath tumors (MPNSTs), benign neurofib

61 tosis 1 and its lethal derivative, malignant peripheral nerve sheath tumors (MPNSTs), is thought to r

62 this approach is being applied to malignant peripheral nerve sheath tumors (MPNSTs), rare Schwann ce

63 e mutations in Nf1 and p53 develop malignant peripheral nerve sheath tumors (MPNSTs), which supports

64 small subset of which progress to malignant peripheral nerve sheath tumors (MPNSTs).

65 that frequently progress to become malignant peripheral nerve sheath tumors (MPNSTs).

66 ve Schwann cell neoplasms known as malignant peripheral nerve sheath tumors (MPNSTs).

67 s can transform spontaneously into malignant peripheral nerve sheath tumors (MPNSTs).

68 risk for transformation of NFs to malignant peripheral nerve sheath tumors (MPNSTs).

69 eatly increased risk of developing malignant peripheral nerve sheath tumors (MPNSTs).These cancers ar

70 , five osteosarcomas (n = 27), one malignant peripheral-nerve sheath tumor (n = 7), 0 rhabdomyosarcom

71 of the disease are the development of benign peripheral nerve sheath tumors (neurofibromas), which ca

72 oma-pheochromocytoma, and two with malignant peripheral nerve sheath tumor (PNST) that arose in a gan

73 tly were found to be comutated in high-grade peripheral nerve sheath tumors (PNST) in mice.

74 ities that histologically resemble malignant peripheral nerve sheath tumors, rare neoplasms that occu

75 sion of plexiform neurofibromas to malignant peripheral nerve sheath tumors requires additional genet

76 ated varying degrees of C-->U RNA editing in peripheral nerve-sheath tumor samples (PNSTs) from patie

77 Dermal and plexiform neurofibromas are peripheral nerve sheath tumors that arise frequently in

78 Schwannomas are common peripheral nerve sheath tumors that can cause debilitati

79 Intraneural perineuriomas are benign peripheral nerve sheath tumors that cause progressive de

80 Schwannomas are peripheral nerve sheath tumors that often occur in the s

81 e molecular pathogenic pathways of malignant peripheral nerve sheath tumors, these mutant zebrafish l

82 erentiated chondrosarcoma, and one malignant peripheral nerve sheath tumor) were analyzed.

83 as neurofibromas, schwannomas, and malignant peripheral nerve sheath tumors, were presented.

84 absence of TGF-beta receptor II in malignant peripheral nerve sheath tumors, which correspond to tumo